Medicine Description
About SITAGLIPTIN Antidiabetic agent, Oral hypoglycaemic Mechanism of Action of SITAGLIPTIN Vildagliptin is a dipeptidylpeptidase-4 (DPP-4) inhibitor that improves glycaemic control by preventing DPP-4 from inactivating the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thus prolonging incretin activity in response to ingestion of nutrients. This increases insulin sensitivity, decreases glucagon secretion and improves ?-cell function. Indications for SITAGLIPTIN Type 2 Diabetes mellitus Interactions for SITAGLIPTIN Digoxin: Increase concentration of digoxin Increased risk of hypoglycaemia when used with other anti-diabetic agents